1259O A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L)

Autor:	D. Fujimoto, Y. Toi, Nobuyuki Katakami, Naoki Furuya, Motoko Tachihara, Noriyuki Miura, Kazumi Nishino, Hidetoshi Hayashi, Nobuyuki Yamamoto, Koichi Azuma, S. Hara, Junichi Shimizu, Sakiko Otani, Satoshi Morita, Kazuhiko Nakagawa, Shunsuke Teraoka
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Lung Bevacizumab business.industry Phases of clinical research EGFR T790M Hematology medicine.disease medicine.anatomical_structure Internal medicine Mutation (genetic algorithm) medicine Adenocarcinoma Osimertinib business medicine.drug
Zdroj:	Annals of Oncology. 31:S813-S814
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::05a2f84c425b927bb305cde9914af674 https://doi.org/10.1016/j.annonc.2020.08.1573 Zobrazit plný text záznamu